Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

Prenatal screening and diagnosis involve testing for conditions in a fetus before it is born, with the aim of detecting causes of birth defects, abnormalities, and genetic conditions. Advancing the prenatal care services provided across the globe has become an uphill battle for medical practitioners and drug makers. Fortunately, this struggle is being eased by the active participation of parents from all around the world in protecting the health of their soon-to-be-born babies through prenatal disease detection methods. Noninvasive prenatal testing (NIPT) procedures are, hence, being rapidly adopted, which is prompting healthcare service providers to increase their focus on such prenatal diagnosis & screening services. Application of the technique to analyze approximately 20,000 genetic features in a single reaction in a sensitive and accurate manner for detection of a wide range of genetic disorders with fewer false positives is expected to propel the demand for NIPT products in the coming years.

The vendors are increasingly entering into partnerships and collaborations to extend their product offerings, increase their market shares, and expand their operations. These partnerships and collaborations help vendors enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. For instance, in 2015, Human Longevity entered into collaboration with Roche Diagnostics to conduct whole-genome sequencing of Roche Diagnostics' subsidiary Genentech's de-identified samples. The partnership helped Roche Diagnostics analyze patient samples based on precise genetic categories and discover new diagnostics and targeted therapies. These partnerships and collaborative activities are accelerating drug discovery efforts, which will lead to the development of new therapies to detect chromosomal abnormalities in neonates. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

Based on test type, the non-invasive prenatal testing market is been segmented into panel 1, panel 2 and panel 3 tests. Based on end-user the non-invasive prenatal testing market is segmented into hospitals, diagnostic centers, and maternity clinics.

The global NIPT market is highly fragmented owing to the presence of several well-established global and regional vendors. The majority of vendors are looking to expand their businesses in the APAC region, which is a major untapped market that is likely to grow at a rapid pace during the forecast period. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

Some of the key players in the non-invasive prenatal testing market include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc. The participants are engaged in the development and licensing of the software and cloud-based distribution model to enhance technology transfer. For instance, Natera underwent a licensing agreement with Unilab, which enables Unilab to access the proprietary protocols and key technology of Natera, thus driving revenue share of the company in reproductive genetic testing.